Close
Xylem
Novotech

Dr. Reddy’s introduces Desloratadine ODT in US

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Novartis and Antares Therapeutics Form Strategic Partnership for Cancer Drug Development

Novartis has finalized a significant collaboration agreement with Antares...

Continuous Manufacturing Reshaping Drug Formulation

Continuous manufacturing drug formulation represents the most significant leap...

3D Printed Dosage Forms Advancing Precision Medicine

The pharmaceutical industry is currently witnessing a transformative shift...
- Advertisement -

Dr. Reddy’s Laboratories has received the FDA approval and introduced Desloratadine orally disintegrating tablets (ODT) in 2.5mg and 5mg strengths in the US.

Desloratadine ODT is a generic equivalent to Clarinex Reditabs (desloratadine), which according to IMS Health data had total sales of $5.3m in the US for the twelve months ending November 2012.

The company makes Desloratadine ODT of 2.5mg and 5mg strengths available in unit dose packages of 30.

Clarinex Reditabs is indicated to fight allergy with the same strength of Clarinex but with the additional convenience of a rapid disintegration without water.

The prescription nonsedating, antihistamine was approved for the treatment of indoor and outdoor allergies and hives of unknown cause.

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Novartis and Antares Therapeutics Form Strategic Partnership for Cancer Drug Development

Novartis has finalized a significant collaboration agreement with Antares...

Continuous Manufacturing Reshaping Drug Formulation

Continuous manufacturing drug formulation represents the most significant leap...

3D Printed Dosage Forms Advancing Precision Medicine

The pharmaceutical industry is currently witnessing a transformative shift...

Real World Data Optimizing Drug Formulation Decisions

The pharmaceutical industry is currently undergoing a data-driven revolution...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »